Masitinib is primarily used in the treatment of certain cancers and inflammatory diseases. It is particularly effective in targeting mast cells and a limited number of kinases, which play a crucial role in the progression of these conditions. In veterinary medicine, it has been employed to treat mast cell tumors in dogs, showing promising results in reducing tumor size and improving survival rates. In human medicine, masitinib is being investigated for its potential in treating diseases such as multiple sclerosis, Alzheimer's disease, and certain types of cancer, including gastrointestinal stromal tumors (GISTs) and melanoma. Its ability to modulate the immune response and inhibit specific pathways involved in disease progression makes it a valuable therapeutic option. Clinical trials continue to explore its efficacy and safety in various medical applications, aiming to expand its use in both human and veterinary healthcare.